News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ImmuPharma plc’s Cancer Drug Candidate IPP- 204106 Shows Complete Response to Tumours in Multiple Human Cancer Cell Lines
May 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, May 20, 2008-ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today pre-clinical data on its new cancer drug, IPP-204106.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Insights
Inside Germany’s biotech capital infrastructure and innovation engine
May 21, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Deals
Lilly and Engage Bio tie the knot with $202M acquisition
May 20, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Beam one-ups Wave as both show promise of genetic editing for AATD
May 20, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
May 20, 2026
·
2 min read
·
Tristan Manalac
